ArticleFrontiers in oncology2026
Exceptional long-term survival in pulmonary large-cell neuroendocrine carcinoma with brain metastases: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a rare and aggressive malignancy, with a poor prognosis and limited therapeutic options, particularly in advanced stages with brain metastases. Long-term survival in metastatic LCNEC is exceedingly uncommon. Case presentation: We report a case of a 32-year-old female diagnosed with stage IV pulmonary LCNEC in 2015. Over a 10-year disease course, she underwent a comprehensive, multimodal treatment approach, including chemotherapy, targeted therapy, two craniotomies, whole-brain radiotherapy, and resection of pelvic metastases. Serial imaging revealed prolonged stability of pulmonary lesions and dynamic control of brain metastases. Longitudinal monitoring of pro-gastrin-releasing peptide (PRO-GRP) levels showed a strong correlation with tumor progression. Molecular profiling identified RB1 and SDHD copy number loss, among other alterations. The patient remains alive 115 months after diagnosis and over 50 months after initial brain metastasis, representing one of the longest documented survivals in metastatic LCNEC. Conclusion: This case demonstrates that prolonged survival in stage IV LCNEC with brain metastases is possible through individualized multimodal therapy and close longitudinal monitoring. It underscores the potential value of molecular profiling and biomarkers like PRO-GRP in treatment planning and disease tracking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.